NASDAQ · NTBL
Healthcare · Biotechnology
$0.25
Down-$0.09 (-27.68%)
Updated Aug 22, 2026, 8:02 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NTBL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NTBL.
NTBL research
Company profile and research snapshot.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 20, 2024 | JMP Securities | Market Perform | — |
| May 16, 2024 | Chardan Capital | Buy | — |
| Apr 15, 2024 | JMP Securities | Market Outperform | — |
| Apr 15, 2024 | Chardan Capital | Buy | — |
| Dec 19, 2023 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 24, 2024
Notable Labs, a clinical-stage precision oncology company, announced progress for its Phase 2 volasertib program in relapsed refractory acute myeloid leukemia. The company received FDA clearance and agreed on a dosing plan for the Phase 2 study, which is expected to initiate enrollment in the coming months.
Zacks Investment Research · May 24, 2024
Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks Investment Research · Apr 19, 2024
Notable Labs (NTBL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewswire Inc. · Apr 12, 2024
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December 31, 2023 and provided a business update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NTBL.
No results
No recent SID articles mention NTBL.
